Literature DB >> 19351830

Detection of precancerous cervical lesions is differential by human papillomavirus type.

Mahboobeh Safaeian1, Mark Schiffman, Julia Gage, Diane Solomon, Cosette M Wheeler, Philip E Castle.   

Abstract

Epidemiologic studies have reported the underrepresentation of cervical precancerous lesions caused by human papillomavirus (HPV) types 18 and 45 (HPV18/45) compared with the proportion of cervical cancers attributed to these HPV types. We investigated the timing of diagnosis of histologic cervical intraepithelial neoplasia grade 3 or worse (CIN3+) using data from the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study (ALTS). Of the 2,725 women who underwent enrollment colposcopy, 412 of 472 (87.3%) diagnosed with histologic CIN3+ over the 2-year duration of ALTS could be assigned to a HPV type or group of types and were included in this analysis. Eighty-four percent of HPV16-positive CIN3+ were diagnosed at enrollment, compared with 57% of HPV18/45-positive CIN3+, and 58% of CIN3 positive for other carcinogenic HPV types at enrollment. In contrast, only 8% of HPV16-positive CIN3+ were diagnosed at exit, whereas 31% were HPV18/45 positive and 22% were positive for other carcinogenic types at study exit (P < 0.001). These results indicate the underrepresentation of HPV18/45 in precancers, whereas HPV16-associated CIN3+ is diagnosed much earlier. Whether the underrepresentation of 18/45 may be due to occult pathology needs further investigation.

Entities:  

Mesh:

Year:  2009        PMID: 19351830      PMCID: PMC3155840          DOI: 10.1158/0008-5472.CAN-08-4192

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. The Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study (ALTS) Group.

Authors: 
Journal:  J Natl Cancer Inst       Date:  2000-03-01       Impact factor: 13.506

2.  Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

Authors:  Jennifer S Smith; Lisa Lindsay; Brooke Hoots; Jessica Keys; Silvia Franceschi; Rachel Winer; Gary M Clifford
Journal:  Int J Cancer       Date:  2007-08-01       Impact factor: 7.396

3.  Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.

Authors:  D Solomon; M Schiffman; R Tarone
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

4.  ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants.

Authors:  M Schiffman; M E Adrianza
Journal:  Acta Cytol       Date:  2000 Sep-Oct       Impact factor: 2.319

5.  Determinants of genital human papillomavirus detection in a US population.

Authors:  C L Peyton; P E Gravitt; W C Hunt; R S Hundley; M Zhao; R J Apple; C M Wheeler
Journal:  J Infect Dis       Date:  2001-05-09       Impact factor: 5.226

6.  An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS).

Authors:  Philip E Castle; J Thomas Cox; Jose Jeronimo; Diane Solomon; Cosette M Wheeler; Patti E Gravitt; Mark Schiffman
Journal:  Obstet Gynecol       Date:  2008-04       Impact factor: 7.661

7.  A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2003-06       Impact factor: 8.661

8.  Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2003-06       Impact factor: 8.661

9.  Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis.

Authors:  G M Clifford; J S Smith; T Aguado; S Franceschi
Journal:  Br J Cancer       Date:  2003-07-07       Impact factor: 7.640

10.  Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis.

Authors:  G M Clifford; J S Smith; M Plummer; N Muñoz; S Franceschi
Journal:  Br J Cancer       Date:  2003-01-13       Impact factor: 7.640

View more
  12 in total

1.  Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure.

Authors:  Sarah E Coseo; Carolina Porras; Lori E Dodd; Allan Hildesheim; Ana Cecilia Rodriguez; Mark Schiffman; Rolando Herrero; Sholom Wacholder; Paula Gonzalez; Mark E Sherman; Silvia Jimenez; Diane Solomon; Catherine Bougelet; Leen-Jan van Doorn; Wim Quint; Mahboobeh Safaeian
Journal:  Sex Transm Dis       Date:  2011-10       Impact factor: 2.830

2.  Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3.

Authors:  Philip E Castle; Mark Schiffman; Cosette M Wheeler; Nicolas Wentzensen; Patti E Gravitt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07       Impact factor: 4.254

3.  Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy.

Authors:  Mark H Einstein; Katherine M Smith; Thomas E Davis; Kathleen M Schmeler; Daron G Ferris; Ashlyn H Savage; Jermaine E Gray; Mark H Stoler; Thomas C Wright; Alex Ferenczy; Philip E Castle
Journal:  J Clin Microbiol       Date:  2014-04-09       Impact factor: 5.948

4.  Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.

Authors:  Arthi Vijayaraghavan; Molly B Efrusy; Karyn A Goodman; Christopher C Santas; Warner K Huh
Journal:  Gynecol Oncol       Date:  2010-08-14       Impact factor: 5.482

5.  Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease.

Authors:  Beatriz Serrano; Laia Alemany; Sara Tous; Laia Bruni; Gary M Clifford; Thomas Weiss; Francesc Xavier Bosch; Silvia de Sanjosé
Journal:  Infect Agent Cancer       Date:  2012-12-29       Impact factor: 2.965

6.  Long-term CIN3+ risk in women with abnormal cytology; role of hrHPV testing.

Authors:  M Kocken; J Berkhof; F J van Kemenade; J A Louwers; A Zaal; M A E Nobbenhuis; G Kenter; P J F Snijders; C J L M Meijer; T J M Helmerhorst
Journal:  Br J Cancer       Date:  2012-02-14       Impact factor: 7.640

7.  Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance.

Authors:  Xiao-Xian Xu; Jian-Song Zhou; Shu-Hui Yuan; Hua Yu; Han-Mei Lou
Journal:  Int J Environ Res Public Health       Date:  2015-09-02       Impact factor: 3.390

8.  Human Papillomavirus Genotype Distribution in Invasive Cervical Cancer in Pakistan.

Authors:  Asif Loya; Beatriz Serrano; Farah Rasheed; Sara Tous; Mariam Hassan; Omar Clavero; Muhammad Raza; Silvia De Sanjosé; F Xavier Bosch; Laia Alemany
Journal:  Cancers (Basel)       Date:  2016-07-30       Impact factor: 6.639

9.  Expression of geminin, p16, and Ki67 in cervical intraepithelial neoplasm and normal tissues.

Authors:  Yan Xing; Chaojun Wang; Jie Wu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

10.  The influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.

Authors:  Cosette M Wheeler; William C Hunt; Jack Cuzick; Erika Langsfeld; Michael Robertson; Philip E Castle
Journal:  Int J Cancer       Date:  2014-04-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.